1. Biosensor vital sign detects multiple sclerosis progression
- Author
-
Krysko, Kristen M, Akhbardeh, Alireza, Arjona, Jennifer, Nourbakhsh, Bardia, Waubant, Emmanuelle, Gourraud, Pierre Antoine, and Graves, Jennifer S
- Subjects
Clinical and Health Psychology ,Biomedical and Clinical Sciences ,Neurosciences ,Psychology ,Brain Disorders ,Autoimmune Disease ,Multiple Sclerosis ,Clinical Research ,Neurodegenerative ,Neurological ,Adult ,Algorithms ,Cohort Studies ,Disability Evaluation ,Female ,Humans ,Longitudinal Studies ,Male ,Middle Aged ,Multiple Sclerosis ,Chronic Progressive ,Multiple Sclerosis ,Relapsing-Remitting ,Signal Processing ,Computer-Assisted ,Vital Signs ,Wearable Electronic Devices ,Clinical Sciences ,Clinical and health psychology - Abstract
ObjectiveTo determine whether a small, wearable multisensor device can discriminate between progressive versus relapsing multiple sclerosis (MS) and capture limb progression over a short interval, using finger and foot tap data.MethodsPatients with MS were followed prospectively during routine clinic visits approximately every 6 months. At each visit, participants performed finger and foot taps wearing the MYO-band, which includes accelerometer, gyroscope, and surface electromyogram sensors. Metrics of within-patient limb progression were created by combining the change in signal waveform features over time. The resulting upper (UE) and lower (LE) extremity metrics' discrimination of progressive versus relapsing MS were evaluated with calculation of AUROC. Comparisons with Expanded Disability Status Scale (EDSS) scores were made with Pearson correlation.ResultsParticipants included 53 relapsing and 15 progressive MS (72% female, baseline mean age 48 years, median disease duration 11 years, median EDSS 2.5, median 10 months follow-up). The final summary metrics differentiated relapsing from secondary progressive MS with AUROC UE 0.93 and LE 0.96. The metrics were associated with baseline EDSS (UE P = 0.0003, LE P = 0.0007). While most had no change in EDSS during the short follow-up, several had evidence of progression by the multisensor metrics.InterpretationWithin a short follow-up interval, this novel multisensor algorithm distinguished progressive from relapsing MS and captured changes in limb function. Inexpensive, noninvasive and easy to use, this novel outcome is readily adaptable to clinical practice and trials as a MS vital sign. This approach also holds promise to monitor limb dysfunction in other neurological diseases.
- Published
- 2021